Trial Profile
A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2022
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms EUCROSS
- 15 Jun 2022 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results of updated analysis of overall survival were presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 08 May 2020 This trial has been completed in Austria, according to European Clinical Trials Database record.